Home » News » AIM News » Allergy Therapeutics Plc to Present at Jefferies 2017 London Healthcare Conference
Allergy Therapeutics plc

Allergy Therapeutics Plc to Present at Jefferies 2017 London Healthcare Conference

Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announced today that Manuel Llobet, Chief Executive Officer, will be presenting at the Jefferies 2017 Healthcare Conference in London, on Wednesday 15 November at 13:20 GMT.

Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange